Which has better valuation & earnings, ALC or COO?

Alcon has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alcon $10.40B 3.00 $980M $1.31 48.21 Cooper Companies $4.09B 2.52 $374.90M $2.93 18.53

Is ALC or COO more profitable?

Cooper Companies has a net margin of 13.46% compared to Alcon's net margin of 5.92%. Cooper Companies' return on equity of 10.90% beat Alcon's return on equity. Company Net Margins Return on Equity Return on Assets Alcon 5.92% 7.29% 5.09% Cooper Companies 13.46% 10.90% 7.24%

Does the media favor ALC or COO?

In the previous week, Cooper Companies had 31 more articles in the media than Alcon. MarketBeat recorded 36 mentions for Cooper Companies and 5 mentions for Alcon. Alcon's average media sentiment score of 0.29 beat Cooper Companies' score of 0.15 indicating that Alcon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alcon 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cooper Companies 5 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend DXCM or ALC?

DexCom presently has a consensus price target of $91.96, suggesting a potential upside of 8.94%. Alcon has a consensus price target of $84.43, suggesting a potential upside of 33.69%. Given Alcon's higher probable upside, analysts clearly believe Alcon is more favorable than DexCom. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 3 Strong Buy rating(s) 3.04 Alcon 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63

Which has stronger valuation and earnings, DXCM or ALC?

Alcon has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.83 $836.30M $2.53 33.36 Alcon $10.40B 3.00 $980M $1.31 48.21

Is DXCM or ALC more profitable?

DexCom has a net margin of 20.12% compared to Alcon's net margin of 5.92%. DexCom's return on equity of 35.94% beat Alcon's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Alcon 5.92% 7.29% 5.09%

Does the media refer more to DXCM or ALC?

In the previous week, DexCom had 6 more articles in the media than Alcon. MarketBeat recorded 11 mentions for DexCom and 5 mentions for Alcon. DexCom's average media sentiment score of 1.06 beat Alcon's score of 0.29 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alcon 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, MDLN or ALC?

Medline has higher revenue and earnings than Alcon. Medline is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.65 $1.16B $0.79 45.24 Alcon $10.40B 3.00 $980M $1.31 48.21

Is MDLN or ALC more profitable?

Alcon has a net margin of 5.92% compared to Medline's net margin of 0.00%. Alcon's return on equity of 7.29% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Alcon 5.92% 7.29% 5.09%

Does the media prefer MDLN or ALC?

In the previous week, Medline had 15 more articles in the media than Alcon. MarketBeat recorded 20 mentions for Medline and 5 mentions for Alcon. Alcon's average media sentiment score of 0.29 beat Medline's score of 0.19 indicating that Alcon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 6 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alcon 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ALC or WST?

In the previous week, West Pharmaceutical Services had 2 more articles in the media than Alcon. MarketBeat recorded 7 mentions for West Pharmaceutical Services and 5 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 0.57 beat Alcon's score of 0.29 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alcon 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral West Pharmaceutical Services 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ALC or SOLV?

Solventum has lower revenue, but higher earnings than Alcon. Solventum is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alcon $10.40B 3.00 $980M $1.31 48.21 Solventum $8.33B 1.77 $1.56B $8.18 10.57

Is ALC or SOLV more profitable?

Solventum has a net margin of 17.26% compared to Alcon's net margin of 5.92%. Solventum's return on equity of 25.09% beat Alcon's return on equity. Company Net Margins Return on Equity Return on Assets Alcon 5.92% 7.29% 5.09% Solventum 17.26% 25.09% 8.78%

Does the media favor ALC or SOLV?

In the previous week, Solventum had 2 more articles in the media than Alcon. MarketBeat recorded 7 mentions for Solventum and 5 mentions for Alcon. Solventum's average media sentiment score of 0.80 beat Alcon's score of 0.29 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alcon 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Solventum 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alcon (ALC) Competitors

$64.06 +0.93 (+1.47%)

Closing price 03:59 PM Eastern

Extended Trading

$64.94 +0.87 (+1.36%)

As of 07:30 PM Eastern

Compare

ALC vs. COO, DXCM, MDLN, WST, and SOLV

Should you buy Alcon stock or one of its competitors? Alcon's main competitors and comparable companies include Cooper Companies (COO), DexCom (DXCM), Medline (MDLN), West Pharmaceutical Services (WST), and Solventum (SOLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Alcon compare to Cooper Companies?

Alcon (NYSE:ALC) and Cooper Companies (NASDAQ:COO) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Alcon currently has a consensus target price of $84.43, indicating a potential upside of 33.69%. Cooper Companies has a consensus target price of $68.60, indicating a potential upside of 26.34%. Given Alcon's stronger consensus rating and higher probable upside, equities analysts plainly believe Alcon is more favorable than Cooper Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alcon	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63
Cooper Companies	2 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.11

Cooper Companies has a net margin of 13.46% compared to Alcon's net margin of 5.92%. Cooper Companies' return on equity of 10.90% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alcon	5.92%	7.29%	5.09%
Cooper Companies	13.46%	10.90%	7.24%

53.9% of Alcon shares are owned by institutional investors. Comparatively, 24.4% of Cooper Companies shares are owned by institutional investors. 1.5% of Alcon shares are owned by company insiders. Comparatively, 2.1% of Cooper Companies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cooper Companies had 31 more articles in the media than Alcon. MarketBeat recorded 36 mentions for Cooper Companies and 5 mentions for Alcon. Alcon's average media sentiment score of 0.29 beat Cooper Companies' score of 0.15 indicating that Alcon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alcon	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cooper Companies	5 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alcon has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Alcon has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alcon	$10.40B	3.00	$980M	$1.31	48.21
Cooper Companies	$4.09B	2.52	$374.90M	$2.93	18.53

Summary

Alcon beats Cooper Companies on 11 of the 17 factors compared between the two stocks.

How does Alcon compare to DexCom?

DexCom (NASDAQ:DXCM) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 53.9% of Alcon shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.5% of Alcon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

DexCom presently has a consensus price target of $91.96, suggesting a potential upside of 8.94%. Alcon has a consensus price target of $84.43, suggesting a potential upside of 33.69%. Given Alcon's higher probable upside, analysts clearly believe Alcon is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	3.04
Alcon	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63

DexCom has a net margin of 20.12% compared to Alcon's net margin of 5.92%. DexCom's return on equity of 35.94% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Alcon	5.92%	7.29%	5.09%

Alcon has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.83	$836.30M	$2.53	33.36
Alcon	$10.40B	3.00	$980M	$1.31	48.21

In the previous week, DexCom had 6 more articles in the media than Alcon. MarketBeat recorded 11 mentions for DexCom and 5 mentions for Alcon. DexCom's average media sentiment score of 1.06 beat Alcon's score of 0.29 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alcon	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

DexCom has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Alcon has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Summary

DexCom beats Alcon on 12 of the 17 factors compared between the two stocks.

How does Alcon compare to Medline?

Medline (NASDAQ:MDLN) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Alcon has a net margin of 5.92% compared to Medline's net margin of 0.00%. Alcon's return on equity of 7.29% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Alcon	5.92%	7.29%	5.09%

Medline has higher revenue and earnings than Alcon. Medline is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.65	$1.16B	$0.79	45.24
Alcon	$10.40B	3.00	$980M	$1.31	48.21

53.9% of Alcon shares are held by institutional investors. 0.8% of Medline shares are held by company insiders. Comparatively, 1.5% of Alcon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Medline had 15 more articles in the media than Alcon. MarketBeat recorded 20 mentions for Medline and 5 mentions for Alcon. Alcon's average media sentiment score of 0.29 beat Medline's score of 0.19 indicating that Alcon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	6 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alcon	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Medline currently has a consensus price target of $46.88, indicating a potential upside of 31.18%. Alcon has a consensus price target of $84.43, indicating a potential upside of 33.69%. Given Alcon's higher probable upside, analysts clearly believe Alcon is more favorable than Medline.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.83
Alcon	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Alcon beats Medline on 10 of the 16 factors compared between the two stocks.

How does Alcon compare to West Pharmaceutical Services?

Alcon (NYSE:ALC) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Alcon currently has a consensus price target of $84.43, suggesting a potential upside of 33.69%. West Pharmaceutical Services has a consensus price target of $385.33, suggesting a potential upside of 6.00%. Given Alcon's higher possible upside, research analysts plainly believe Alcon is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alcon	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, West Pharmaceutical Services had 2 more articles in the media than Alcon. MarketBeat recorded 7 mentions for West Pharmaceutical Services and 5 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 0.57 beat Alcon's score of 0.29 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alcon	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
West Pharmaceutical Services	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alcon has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Alcon has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alcon	$10.40B	3.00	$980M	$1.31	48.21
West Pharmaceutical Services	$3.07B	8.32	$493.70M	$7.81	46.55

West Pharmaceutical Services has a net margin of 16.98% compared to Alcon's net margin of 5.92%. West Pharmaceutical Services' return on equity of 20.11% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alcon	5.92%	7.29%	5.09%
West Pharmaceutical Services	16.98%	20.11%	14.83%

53.9% of Alcon shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 1.5% of Alcon shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

West Pharmaceutical Services beats Alcon on 11 of the 17 factors compared between the two stocks.

How does Alcon compare to Solventum?

Alcon (NYSE:ALC) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Alcon has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Solventum has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

In the previous week, Solventum had 2 more articles in the media than Alcon. MarketBeat recorded 7 mentions for Solventum and 5 mentions for Alcon. Solventum's average media sentiment score of 0.80 beat Alcon's score of 0.29 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alcon	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Solventum	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.9% of Alcon shares are owned by institutional investors. 1.5% of Alcon shares are owned by company insiders. Comparatively, 0.2% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Solventum has a net margin of 17.26% compared to Alcon's net margin of 5.92%. Solventum's return on equity of 25.09% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alcon	5.92%	7.29%	5.09%
Solventum	17.26%	25.09%	8.78%

Solventum has lower revenue, but higher earnings than Alcon. Solventum is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alcon	$10.40B	3.00	$980M	$1.31	48.21
Solventum	$8.33B	1.77	$1.56B	$8.18	10.57

Alcon presently has a consensus price target of $84.43, indicating a potential upside of 33.69%. Solventum has a consensus price target of $92.80, indicating a potential upside of 7.36%. Given Alcon's higher probable upside, analysts clearly believe Alcon is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alcon	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63
Solventum	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Alcon beats Solventum on 9 of the 17 factors compared between the two stocks.

Get Alcon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALC vs. The Competition

Export

Metric	Alcon	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$31.23B	$5.45B	$7.16B	$22.94B
Dividend Yield	N/A	1.77%	2.53%	3.71%
P/E Ratio	48.90	25.53	274.13	28.60
Price / Sales	3.05	84.23	587.04	24.60
Price / Cash	11.51	31.87	76.38	37.72
Price / Book	1.44	5.93	11.21	4.72
Net Income	$980M	$146.18M	$3.50B	$1.07B
7 Day Performance	0.50%	-0.17%	-0.84%	0.35%
1 Month Performance	-6.39%	-3.15%	-5.42%	-3.80%
1 Year Performance	-13.94%	2.91%	4.38%	6.48%

Alcon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALC Alcon	3.8206 of 5 stars	$64.06 +1.5%	$84.43 +31.8%	-17.5%	$31.23B	$10.40B	48.90	25,942	News Coverage Analyst Forecast
COO Cooper Companies	4.7346 of 5 stars	$56.57 +2.1%	$71.47 +26.3%	-22.7%	$10.53B	$4.09B	19.31	15,000	Trending News Analyst Forecast
DXCM DexCom	4.5813 of 5 stars	$86.68 +0.1%	$89.08 +2.8%	+24.5%	$32.69B	$4.66B	34.26	11,100	Analyst Upgrade
MDLN Medline	2.7467 of 5 stars	$35.07 +1.1%	$46.88 +33.7%	N/A	$45.62B	$28.43B	44.39	45,000	Analyst Downgrade Insider Trade
WST West Pharmaceutical Services	4.0455 of 5 stars	$375.99 +1.5%	$382.00 +1.6%	+35.7%	$26.07B	$3.07B	48.14	10,800	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ALC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alcon (ALC) Competitors

ALC vs. COO, DXCM, MDLN, WST, and SOLV

How does Alcon compare to Cooper Companies?

Summary

How does Alcon compare to DexCom?

Summary

How does Alcon compare to Medline?

Summary

How does Alcon compare to West Pharmaceutical Services?

Summary

How does Alcon compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALC vs. The Competition

Alcon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alcon (ALC) Competitors

ALC vs. COO, DXCM, MDLN, WST, and SOLV

How does Alcon compare to Cooper Companies?

Do analysts rate ALC or COO?

Is ALC or COO more profitable?

Do institutionals & insiders hold more shares of ALC or COO?

Does the media favor ALC or COO?

Which has more risk and volatility, ALC or COO?

Which has better valuation & earnings, ALC or COO?

Summary

How does Alcon compare to DexCom?

Do institutionals and insiders have more ownership in DXCM or ALC?

Do analysts recommend DXCM or ALC?

Is DXCM or ALC more profitable?

Which has stronger valuation and earnings, DXCM or ALC?

Does the media refer more to DXCM or ALC?

Which has more risk and volatility, DXCM or ALC?

Summary

How does Alcon compare to Medline?

Is MDLN or ALC more profitable?

Which has better valuation and earnings, MDLN or ALC?

Do insiders & institutionals believe in MDLN or ALC?

Does the media prefer MDLN or ALC?

Do analysts prefer MDLN or ALC?

Summary

How does Alcon compare to West Pharmaceutical Services?

Do analysts prefer ALC or WST?

Does the media prefer ALC or WST?

Which has more risk & volatility, ALC or WST?

Which has better valuation & earnings, ALC or WST?

Is ALC or WST more profitable?

Do institutionals and insiders hold more shares of ALC or WST?

Summary

How does Alcon compare to Solventum?

Which has more volatility and risk, ALC or SOLV?

Does the media favor ALC or SOLV?

Do institutionals and insiders have more ownership in ALC or SOLV?

Is ALC or SOLV more profitable?

Which has stronger earnings and valuation, ALC or SOLV?

Do analysts rate ALC or SOLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALC vs. The Competition

Alcon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools